Alnylam poaches VP from Bristol-Myers Squibb
pharmafile | November 4, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Alnylam, pushkal garg
US-based RNAi therapeutics firm Alnylam Pharmaceuticals has appointed Dr Pushkal Garg to the position of senior vice president of its clinical development unit.
At Alnylam Garg will join the existing development team and be responsible for managing the company’s clinical research, clinical operations, and biometrics functions.
He joins Alnylam with 15 years of experience in clinical drug development and most recently served as a vice president in the Immunoscience division at Bristol-Myers Squibb (BMS). In this role he was responsible for its leadership development across immune-mediated diseases in the areas of rheumatology, gastroenterology, nephrology, and transplantation.
Prior to his eight-year tenure at BMS, Garg was at Millennium Pharmaceuticals where he worked in various roles of increasing responsibility overseeing the development of multiple small molecule and biologic therapeutics for the treatment of inflammatory disorders.
Akshay Vaishnaw, executive VP and chief medical officer of Alnylam says: “We are delighted to welcome Pushkal to the Alnylam team. Pushkal brings a deep understanding of the biotechnology and pharmaceutical industries, extensive experience, as well as a proven track record of success, and I am excited to have him join our team as we expand our clinical development capabilities.”
Garg adds: “I am thrilled to be joining Akshay and the broader Alnylam development team at this important stage, as we advance our pipeline of novel therapies through the clinic. I look forward to being part of a team that is so passionate and committed to advancing RNAi therapeutics to patients.”
Related Content
Alnylam and Roche partner for RNAi therapeutic for treatment of hypertension
Alnylam Pharmaceuticals has announced that it has entered a strategic agreement with Roche for the …
Alnylam shares positive results from phase 1 trial
Alnylam Pharmaceuticals has announced positive interim results for the ongoing single ascending dose section of …
Alnylam’s lumasiran hits main Phase 3 goal in rare renal disease primary hyperoxaluria type 1
Alnylam has presented promising new Phase 3 data at the European Renal Association-European Dialysis and …
